2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
about
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesSacubitril/valsartan in heart failure: latest evidence and place in therapyRole of circulating factors in cardiac aging.A U-shaped association of body mass index and all-cause mortality in heart failure patients: A dose-response meta-analysis of prospective cohort studies.Danon disease for the cardiologist: case report and review of the literatureSerelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.Pulmonary Function and Arterial Stiffness in Chronic Heart Failure.Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combinationSubclinical Atherosclerosis, Cardiac and Kidney Function, Heart Failure, and Dementia in the Very Elderly.Assessment of dyssynchrony by gated myocardial perfusion imaging does not improve patient management.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.Treatment of Hyperkalemia in Heart Failure.Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?Medication adherence: staying within the boundaries of safety.Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure.Potential Expanded Indications for Neprilysin Inhibitors.First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).Turning Failure into Success: Trials of the Heart Failure Clinical Research Network.Ivabradine: A Review of Labeled and Off-Label Uses.Hospice Enrollment in Patients With Advanced Heart Failure Decreases Acute Medical Service Utilization.Understanding the economic burden of heart failure in China: impact on disease management and resource utilization.Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.Immunosuppression and adult heart transplantation: emerging therapies and opportunities.Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis.Coronary artery disease prevalence and outcome in patients hospitalized with acute heart failure: an observational report from seven Middle Eastern countries.Current Pharmacological Therapies in Heart Failure Patients.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management.Rationales and choices for the treatment of patients with NYHA class II heart failure.Heart failure with reduced ejection fraction.Shocks after implantable cardioverter-defibrillator implantation in idiopathic cardiomyopathy patients: a myocardial biopsy study.Values of hemodynamic variation in response to passive leg raising in predicting exercise capacity of heart failure with preserved ejection fraction.Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).
P2860
Q26741152-487B88A4-BA14-4C20-86A4-BF9805201A70Q28070191-56701B14-07C0-4B14-A1E7-FD21118668AEQ30234641-08A5DA3F-987D-4B2D-ABB8-69A95C6BBE45Q30244073-6B4D3DF0-11FD-4F67-938E-923B63863D24Q33806044-82D24683-6776-40BA-8E2E-733403F52D84Q33845755-135AF07A-1F77-4BD3-9F47-CD3B42F0C812Q36405279-0A9E0BE9-A461-4BC1-8CAE-AC5C1E1B5B77Q37554044-9A79F821-0C66-4135-B0B2-3111C967464EQ37597972-5F90A18F-F921-4A05-8496-763659E11F35Q38373457-5E71B853-24E3-431A-B1BA-FD8100730073Q38632780-DB93C431-D31D-4B30-82DA-8BC4D40B539BQ38663003-16ABBCA3-28EF-4288-B2FC-426F77E2F266Q38685645-C0B9A4F9-4FAA-4ABF-9E3B-CFE0F11B64F2Q38686407-E87B3574-AE6E-42FE-84B3-5855819040FBQ38705827-92E87E5E-B7F5-45E2-BB3B-A97D0B12BB78Q38731482-401E0942-B90D-42A1-80D0-3F4AB36C1A98Q38732538-61B65A19-D7BD-450D-AACC-182874BCFA4BQ38737757-B31BE1DF-DAB6-463A-BF8C-692096AD8BF7Q38747742-F573997E-A25C-4FEC-905C-D8B55E21E918Q38781645-933F0255-C46A-4A53-98B3-70B9DA16CABCQ38799792-C218FD41-1A28-41D0-B596-F4F289AB840AQ38802222-C748D397-7BD3-498F-88C8-E8141B4B4ED7Q38894220-DF20530D-F11B-4D7F-8901-0929B6AAA282Q38908357-E0947BDE-3011-4FD3-966A-7167C111B4E9Q38911814-EEA81D30-B57B-48D8-9F71-BF619D472187Q38944593-E1E15CFD-282A-4C9E-AE11-E0FA68FDC751Q39011741-44346A21-9854-4C24-9AD1-32E95BA36F91Q39029380-555151FF-2C63-4543-8E95-2A0652C49F50Q39176836-90992933-0DDB-437F-929D-69558F21A182Q39200756-5DAA4ABA-E9B9-4418-AB80-F3445DD9209BQ39204290-D59BD1D4-32BA-47AF-96F4-9C61DE8B35D6Q39247505-344E5AD3-3295-42E8-9CF7-FE0D2B090302Q39264105-21AEC486-EA9E-4283-A7C1-1977D0CBAC8AQ39317320-7A73768B-8DC5-491B-A040-FEF1316C9D3DQ39410727-6ADE32DD-4765-45A8-B08A-DDB7E8B793E0Q40081533-78144267-7E33-46B7-B179-491D1786A68FQ40082981-106EE189-798A-4F78-858B-C74BE4D1B94DQ41482180-C4ECF491-D468-47C5-B29D-24EE5D71A3A1Q41628438-28373846-5DA1-4515-AEA4-4E5A8F0B11E0Q41686268-044FDC59-28E4-4851-B17A-B1703CF6F228
P2860
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
description
im September 2016 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2016
@uk
name
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@en
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@nl
type
label
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@en
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@nl
prefLabel
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@en
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@nl
P2093
P50
P1476
2016 ACC/AHA/HFSA Focused Upda ...... he Management of Heart Failure
@en
P2093
Biykem Bozkurt
Cheryl Westlake
Donald E. Casey
JoAnn Lindenfeld
Lynne Warner Stevenson
Mark H. Drazner
Michael M. Givertz
Monica M. Colvin
Pamela N. Peterson
Patrick E. McBride
P304
P356
10.1016/J.JACC.2016.05.011
P407
P577
2016-09-01T00:00:00Z